皮膚科用薬剤の世界市場:皮膚感染症薬、皮膚炎薬、にきび薬、乾癬薬...市場調査レポートについてご紹介

【英文タイトル】Dermatological Drugs Market Forecast 2015-2025 : Opportunities for Leading Companies

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Global Dermatological Drugs: Market Overview
1.2 Global Dermatological Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction To Dermatological Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.2 An Introduction To Dermatology
2.2.1 The Structural Lay-out Of The Skin, Hair, And Nails
2.2.2 Hair And Nails
2.2.3 Sweat And Sebaceous Glands
2.2.4 Functions Of The Skin
2.3 Common Skin Diseases
2.4 Acne: The Most Common Skin Disease
2.4.1 Acne: Epidemiology
2.4.2 Acne: Causes And Pathogenesis
2.4.3 Acne: Treatment
2.5 Dermatitis: Inflammation Of The Skin
2.5.1 Atopic Dermatitis
2.5.2 Contact Dermatitis
2.5.3 Seborrhoeic Dermatitis
2.5.4 Nummular Dermatitis
2.5.5 Perioral Dermatitis
2.6 Psoriasis: A Complex Multi-factorial Disease
2.7 Rosacea: Vascular Instability
2.8 Alopecia: Excessive Shedding Of Hair
2.9 Skin Infections: A Serious Healthcare Threat
2.9.1 Bacterial Skin Infections
2.9.2 Fungal Skin Infections
2.9.3 Viral Skin Infections
2.10 Common Skin Treatments
2.10.1 Creams and Semisolid Emulsions
2.10.2 Ointments
2.10.3 Lotions
2.10.4 Solutions
2.10.5 Occlusive Therapy
2.10.6 Cleansing Agents
2.10.7 Powders and Hydrophilic Polymer
2.10.8 Anti-Infective Agents
2.10.9 Anti-Inflammatory Agents
2.11 Phases Of Clinical Trials
2.12 Dermatological Drugs: Market Definition In This Report

3. The Global Dermatological Drugs Market, 2015-2025
3.1 The Global Dermatological Drugs Market: Market Overview
3.2 Categorisation Of The Global Dermatological Drugs Market
3.3 The Global Dermatological Drugs Market In 2014
3.4 The Global Dermatological Drugs Market: Market Forecast 2015-2025
3.5 Dermatological Drugs: Changing Market Shares By Sector 2015-2025

4. The Psoriasis Drugs Market: Market Analysis And Forecast 2015-2025
4.1 Psoriasis Treatments: The Dominance Of Biologics
4.1.1 Leading Products In The Psoriasis Drugs Market, 2014
4.2 Psoriasis: Market Trends And Developments, 2015
4.2.1 Biological Drugs In Psoriasis Treatment: A Brief Overview
4.2.2 Issues Around Patent Protection, The Threat Of Biosimilars And Pricing
4.2.3 The Disadvantages Of Biologics In Psoriasis Treatment
4.3 Psoriasis Drugs: Market Forecast 2015-2025
4.3.1 Psoriasis Drugs: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Drugs Used In The Treatment Of Psoriasis
4.5 Humira (adalimumab) – AbbVie
4.5.1 Humira: Historical Sales Analysis, 2010-2014
4.5.2 Humira: Sales Forecast 2015-2025
4.5.3 Future Prospects For Biosimilar Versions Of Humira
4.6 Stelara (ustekinumab) – Johnson & Johnson
4.6.1 Stelara: Historical Sales Analysis, 2010-2014
4.6.2 Stelara: Sales Forecast 2015-2025
4.6.3 Intensifying Competition For Stelara
4.7 Enbrel (etanercept) – Amgen/ Pfizer/ Takeda
4.7.1 Enbrel: Co-Promotions And Marketing Rights
4.7.2 Enbrel: Historical Sales Analysis, 2008-2014
4.7.3 Enbrel: Patent Expiries and Potential Competition, 2015-2025
4.7.4 Enbrel: Sales Forecast 2015-2025
4.7.5 Enbrel Auto-injector Pens: A Driver Of Growth In Recent Years
4.7.6 Competition From Other Drugs
4.7.7 Biosimilar Competition For Enbrel
4.8 Remicade (infliximab) – Johnson & Johnson
4.8.1 Remicade: Historical Sales Analysis, 2010-2014
4.8.2 Remicade: Patent Expiries and Potential Competition, 2015-2025
4.8.3 Remicade: Sales Forecast 2015-2025
4.9 Daivobet (betamethasone/calcipotriene) – LEO Pharma
4.9.1 Daivobet: Sales Forecast 2015-2025
4.9.2 LEO Pharma’s Life Cycle Management Of Daivobet
4.9.3 Daivobet/Dovobet/Taclonex – Generic Competition
4.10 Soriatane (acitretin) – GlaxoSmithKline
4.10.1 Soriatane: Sales Forecast 2015-2025
4.11 Other Psoriasis Drugs
4.11.1 Cimzia (certolizumab) – UCB
4.11.2 Cosentyx (secukinumab) – Novartis
4.11.3 Otezla (apremilast) – Celgene
4.11.4 Sorilux (calcipotriene foam) – GSK
4.11.5 Other Psoriasis Drugs: Sales Forecast 2015-2025
4.12 Psoriasis Drugs Market: Summary

5. Skin Infection Drugs Market: Market Analysis And Forecast 2015-2025
5.1 Skin Infection Drugs: Abundant Growth Opportunities
5.1.1 Leading Products In The Skin Infection Drugs Market, 2014
5.2 Skin Infection Drugs: Market Forecast 2015-2025
5.2.1 Skin Infection Drugs: Changing Market Shares By Leading Drugs 2015-2025
5.3 Leading Drugs Used In The Treatment Of Skin Infections
5.4 Cubicin (daptomycin) – Cubist Pharmaceuticals/ Merck & Co
5.4.1 Acquisition By Merck & Co
5.4.2 Generic Competition For Cubicin
5.4.3 Cubicin: Sales Forecast 2015-2025
5.4.4 Lifecycle Management Strategies For Cubicin
5.5 Zyvox (linezolid) – Pfizer
5.5.1 Zyvox: Historical Sales Analysis, 2010-2014
5.5.2 Zyvox: Sales Forecast 2015-2025
5.5.3 The Threats To Zyvox Sales From Competing New Drugs
5.6 Valtrex (valaciclovir) – GSK
5.6.1 Valtrex: Historical Sales Analysis, 2010-2014
5.6.2 Valtrex: Sales Forecast 2015-2025
5.7 Canesten (clotrimazole) – Bayer
5.7.1 Canesten: Historical Sales Analysis, 2011-2014
5.7.2 Canesten: Sales Forecast 2015-2025
5.8 Lamisil (terbinafine) – Novartis
5.8.1 Lamisil Patent Expiry
5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
5.8.3 Lamisil: Sales Forecast 2015-2025
5.9 Bactroban (mupirocin) – GSK
5.9.1 Bactroban: Historical Sales Analysis, 2010-2013
5.9.2 Bactroban: Sales Forecast 2015-2025
5.10 Other Skin Infection Drugs
5.10.1 Dalvance (dalbavancin) – Durata Therapeutics
5.10.2 Jublia (efinaconazole) – Valeant
5.10.3 Kerydin (tavaborole) – Anacor
5.10.4 Sivextro (tedizolid) – Cubist Pharmaceuticals
5.10.5 Zovirax (acyclovir) – Valeant/GSK
5.10.5.1 Valeant Acquires Zovirax In US And Canada
5.10.5.2 Mylan’s Generic Zovirax And Actavis’ Authorised Generic
5.10.6 Other Skin Infection Drugs: Sales Forecast 2015-2025
5.11 Skin Infection Drugs: Market Summary

6. Acne Drugs Market: Market Analysis And Forecast 2015-2025
6.1 Acne Drugs: A Diversified Market
6.1.1 Leading Products In The Acne Drugs Market, 2014
6.2 Acne Drugs Market: Recent Trends and Developments
6.2.1 The Rise Of Combination Therapies In Acne Treatment
6.2.2 Oral Contraceptives In Treating Acne
6.2.3 The Threat Of Generic Competition In The Acne Drugs Market
6.3 Acne Drugs: Market Forecast 2015-2025
6.3.1 Acne Drugs: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Drugs In The Acne Drugs Market
6.5 Solodyn (minocycline) – Valeant
6.5.1 Solodyn: Sales Forecast 2015-2025
6.5.2 Antitrust Action Over Solodyn Pay-For-Delay Deals
6.5.3 Impax And Medicis Collaborating On Advanced Solodyn
6.5.4 Medicis And Lupin Settle
6.6 Epiduo (adapalene/benzoyl peroxide) – Galderma/ Nestlé Skin Health
6.6.1 Epiduo: Sales Forecast 2015-2025
6.6.2 Galderma Settlement Agreement Over Generic Epiduo
6.6.3 Paediatric Approval For Epiduo
6.7 Claravis (isotretinoin) – Teva
6.7.1 Claravis: Sales Forecast 2015-2025
6.8 Aczone (dapsone) – Allergan
6.8.1 Aczone: Sales Forecast 2015-2025
6.9 Differin (adapalene) – Galderma/ Nestlé Skin Health
6.9.1 Recent Generic Competition To Differin
6.9.2 Differin: Sales Forecast 2015-2025
6.9.3 Federal Circuit Court Invalidates Differin Patents
6.10 Absorica/Epuris (CIP-isotretinoin) – Cipher/ Sun Pharma
6.10.1 Absorica/Epuris: Sales Forecast 2015-2025
6.11 Ziana (clindamycin/tretinoin) – Valeant Pharmaceuticals International
6.11.1 Valeant’s Patent Settlement With Actavis Over Ziana
6.11.2 Ziana: Sales Forecast 2015-2025
6.12 Doryx (doxycycline) – Actavis/ Mayne Pharma
6.12.1 Lifecycle Management Strategies For Doryx
6.12.2 Divestment Agreement With Mayne Pharma
6.12.3 Generic Competition For Doryx
6.12.4 Doryx: Sales Forecast 2015-2025
6.13 Other Acne Drugs
6.13.1 Acanya (clindamycin/benzoyl peroxide) – Dow / Valeant
6.13.1.1 Acanya: Financial Analysis
6.13.1.2 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
6.13.1.3 Legal Battles Involving Dow/Valeant, Perrigo, And Watson
6.13.2 Amnesteem (isotretinoin) – Mylan
6.13.2.1 Amnesteem: Financial Analysis
6.13.3 Diane (cyproterone/ethinyl estradiol) – Bayer
6.13.4 Duac (clindamycin/benzoyl peroxide) – GlaxoSmithKline
6.13.4.1 Duac: Financial Analysis
6.13.5 Veltin (tretinoin/clindamycin) – GSK
6.13.6 Other Acne Drugs: Sales Forecast 2015-2025
6.14 Acne Drugs: Market Summary

7. Dermatitis Drugs Market: Market Analysis And Forecast 2015-2025
7.1 Dermatitis Drugs: High Generic Penetration
7.1.1 Leading Products In The Dermatitis Drugs Market, 2014
7.2 Dermatitis Drugs: Market Forecast 2015-2025
7.2.1 Dermatitis Drugs: Changing Market Shares By Leading Drugs 2015-2025
7.3 Leading Drugs In The Dermatitis Drugs Market
7.4 Bepanthen (dexpanthenol)/ Bepanthol – Bayer
7.4.1 Bepanthen: Sales Forecast 2015-2025
7.5 Protopic (tacrolimus) – Astellas Pharma/ Roche
7.5.1 Protopic Benefits From Expanded Indication
7.5.2 Generic Competition For Protopic
7.5.3 Protopic: Sales Forecast 2015-2025
7.6 Elidel (pimecrolimus) – Meda Pharma/ Valeant
7.6.1 Elidel: Sales Forecast 2015-2025
7.7 Elocon (mometasone) – Merck & Co
7.7.1 Elocon: Sales Forecast 2015-2025
7.8 Other Dermatitis Drugs: Sales Forecast 2015-2025
7.9 Dermatitis Drugs: Market Outlook

8. Leading National Markets For Dermatological Drugs, 2015-2025
8.1 The Dermatological Drugs Market By Region
8.1.1 The Global Distribution Of Dermatological Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Dermatological Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Dermatological Drugs Market
8.4.1 The Impact Of An Expanding Medicare Coverage
8.4.2 Legislative Environment Stimulating Biosimilars Market?
8.4.3 US Dermatological Drugs Market: Market Forecast 2015-2025
8.5 The EU5 Markets: Growth Expected In Each Country
8.5.1 EU5 Dermatological Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 German Dermatological Drugs Market: Market Forecast 2015-2025
8.5.3 France
8.5.3.1 French Dermatological Drugs Market Forecast 2015-2025
8.5.4 UK
8.5.4.1 UK Dermatological Drugs Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italian Dermatological Drugs Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Dermatological Drugs Market Forecast 2015-2025
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Dermatological Drugs Market Forecast 2015-2025
8.7 China
8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China
8.7.2 Improving Public Perception Of Dermatology In China
8.7.3 Price Controls And The Anhui Model
8.7.4 Chinese Dermatological Drugs Market Forecast 2015-2025
8.8 India
8.8.1 The Effects Of The Drug Prices Control Order Of 2013
8.8.2 India’s Expansion Of Healthcare Provision
8.8.3 Indian Dermatological Drugs Market Forecast 2015-2025
8.9 Brazil
8.9.1 The Growth In Brazil’s Healthcare Landscape
8.9.2 Clearer Access To Medicines In Brazil
8.9.3 Brazilian Dermatological Drugs Market Forecast 2015-2025
8.10 Russia
8.10.1 Pharma2020 Strategy – Healthcare And Industry Reform
8.10.2 Russian Dermatological Drugs Market Forecast 2015-2025
8.11 Mexico
8.11.1 Seguro Popular: Mexican Healthcare Reform
8.11.2 Are Multinationals Waking Up To Mexico’s Potential?
8.11.3 Mexican Dermatological Drugs Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 The Rest of the World Dermatological Drugs Market Forecast 2015-2025

9. Leading Companies In The Dermatological Drugs Market, 2015-2025
9.1 Dermatological Drugs – A Rapidly Consolidating Market
9.2 Galderma (Nestle Skin Health S.A.)
9.2.1 Galderma: Dermatological Drugs Portfolio, 2015
9.2.2 Galderma: Recent Developments
9.2.2.1 Nestlé’s Acquisition Of Galderma
9.2.2.2 Approval Of Soolantra For Rosacea
9.2.2.3 Mirvaso Launched For Rosacea
9.3 Johnson & Johnson
9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2015
9.3.2 Johnson & Johnson Dermatological Drugs Sales Forecast 2015-2025
9.3.3 Johnson And Johnson: Dermatological Drug Development Efforts, 2015
9.4 AbbVie
9.4.1 AbbVie: Dermatological Drugs Portfolio, 2015
9.4.2 AbbVie Dermatological Drugs Sales Forecast 2015-2025
9.4.3 AbbVie: Dermatological Drugs Development Pipeline, 2015
9.4.3.1 BT-061 (tregalizumab) For The Treatment Of Psoriasis
9.5 GlaxoSmithKline (GSK)
9.5.1 GSK: Dermatological Drugs Portfolio, 2015
9.5.2 GlaxoSmithKline (GSK) Dermatological Drugs Sales Forecast 2015-2025
9.5.3 GlaxoSmithKline (GSK): Recent Developments
9.5.3.1 Business Restructuring Arrangements With Novartis
9.5.3.2 Tafinlar and Mekinist Combination Approved by FDA, Withdrawn in EU
9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2015
9.6 Pfizer
9.6.1 Pfizer: Dermatological Drugs Portfolio, 2015
9.6.2 Pfizer Dermatological Drugs Sales Forecast 2015-2025
9.6.3 Pfizer: Dermatological Drugs Development Pipeline, 2015
9.7 LEO Pharma
9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2015
9.7.2 LEO Pharma Dermatological Drugs Sales Forecast 2015-2025

10. Dermatological Drugs: Research And Development Pipeline, 2015-2025
10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 New Technology In R&D Pipeline Activities
10.1.1.1 Reformulation
10.1.1.2 Combination Treatments
10.1.1.3 New Mechanisms And Drug Delivery Technologies
10.1.1.4 Potential Market Entrants
10.2 Psoriasis Drugs Development Pipeline, 2015
10.2.1 Psoriasis Drugs In Phase 3 Development
10.2.1.1 000-0551 Lotion (halobetasol) – Therapeutics, Inc
10.2.1.2 AMG 827 (brodalumab) – AstraZeneca/ Amgen
10.2.1.3 CF101 (IB-MECA) – Can-Fite BioPharma
10.2.1.4 CNTO 1959 (guselkumab) – MorphoSys/ Janssen
10.2.1.5 LAS41008 (dimethyl fumarate) – Almirall
10.2.1.6 LEO 90100 – LEO Pharma
10.2.1.7 LY2439821 (ixekizumab) – Eli Lilly
10.2.1.8 MK-3222/SCH 900222 (tildrakizumab) – Merck
10.2.1.9 STF 115469 (calcipotriene foam) – GSK
10.2.1.10 Xeljanz (tofacitinib) – Pfizer
10.2.2 Psoriasis Drugs In Phase 2 Development
10.2.2.1 AN2728 (PDE-4 inhibitor) – Anacor Pharmaceuticals
10.2.2.2 CT327 (TrkA inhibitor) – Creabilis Therapeutics
10.2.2.3 ASP015K (JAK inhibitor) – Astellas Pharma
10.2.2.4 Jakavi/Jakafi (ruxolitinib) – Incyte/ Novartis
10.2.2.5 LY3009104 (baricitinib) – Incyte/ Eli Lilly
10.2.2.6 PH-10 (Rose Bengal) – Provectus Biopharmaceuticals
10.2.3 Psoriasis Drugs In Phase 1 And Pre-clinical Development
10.3 Skin Infection Drugs Development Pipeline, 2015
10.3.1 Drugs In Phase 3 Development For Skin Infections
10.3.1.1 Delafloxacin (delafloxacin) – Melinta Pharmaceuticals
10.3.1.2 NB-001 – NanoBio Corporation
10.3.1.3 Orbactiv/ Nuvocid (oritavancin) – The Medicines Company
10.3.1.4 Luliconazole – Topica Pharmaceuticals
10.3.2 Drugs In Phase 2 Development For Skin Infections
10.3.3 Drugs In Phase 1 And Preclinical Pipeline For Skin Infections
10.4 Acne Drugs Development Pipeline, 2015
10.4.1 Drugs In Phase 3 Development For Acne
10.4.1.1 Duac low dose (clindamycin/ benzoyl peroxide) – GlaxoSmithKline
10.4.1.2 Visonac (photodynamic therapy) – Photocure
10.4.2 Drugs In Phase 2 Development For Acne
10.4.3 Drugs In Phase 1 And Pre-clinical Development For Acne
10.4.4 A Possible Vaccine For Acne
10.5 Dermatitis Drugs Development Pipeline, 2015
10.5.1 Drugs In Phase 3 Development For Dermatitis
10.5.1.1 Toctino (alitretinoin) – GSK
10.5.1.2 Dermadexin and Pruridexin (P3CGM) – Cipher Pharmaceuticals
10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) – Pierre Fabre
10.5.1.4 REGN668/SAR231893 (dupilumab) – Regeneron/ Sanofi
10.5.1.5 Soriatane (acitretin) – InnovaDerm/Tribute Pharmaceuticals
10.5.2 Drugs In Phase 2 Development For Dermatitis
10.5.3 Drugs In Phase 1 And Preclinical Stages Of Development For Dermatitis
10.6 Other Dermatological Drugs Development Pipeline, 2015
10.6.1 Other Dermatological Drugs: Filed or Recently Launched
10.6.1.1 Actikerall (fluorouracil/salicylic acid) – Almirall
10.6.1.2 Ameluz (5-ALA photodynamic therapy) – Biofrontera
10.6.1.3 Keytruda (MK-3475, Pembrolizumab) – Merck
10.6.1.4 Mirvaso (brimonidine) – Galderma
10.6.1.5 Picato (ingenol mebutate) – LEO Pharma
10.6.1.6 Xolair (omalizumab) – Novartis/ Roche
10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2015
10.6.2.1 Atralin (tretinoin) – Valeant
10.6.2.2 BMS-936558 (nivolumab) – Bristol-Myers Squibb
10.6.2.3 CD5024 (ivermectin) – Galderma
10.6.2.4 Latisse (bimatoprost) – Allergan (Actavis)
10.6.2.5 LEE011, LGX818, and MEK162 – Novartis
10.6.2.6 Oleogel-S10 (triterpene extract) – Birken AG
10.6.2.7 PV-10 (Rose Bengal) – Provectus Pharmaceuticals
10.6.2.8 SR-T100 gel (Solanum incanum extract) – G&E Herbal Biotechnology
10.6.2.9 TVEC (talimogene laherparepvec) – Amgen
10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2015
10.6.4 Other Dermatological Drugs: Phase 1 and Preclinical Pipeline

11. Qualitative Analysis Of The Dermatological Drugs Market, 2015-2025
11.1 Market Factors Influencing Dermatological Drugs
11.2 SWOT Analysis Of The Global Dermatological Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 The High Unmet Clinical Need In Dermatology
11.2.1.2 A Healthy Pipeline Of Development-Stage Products
11.2.1.3 Strong Industry-Physician Relationships
11.2.2 Weaknesses
11.2.2.1 Limited Efficacy And Adverse Effects May Impact Product Uptake
11.2.2.2 Patient Adherence – A Major Challenge To Treatment Design
11.2.2.3 Impending Patent Expiries And The Challenges Posed By Generic Competition
11.2.3 Opportunities
11.2.3.1 The High-Growth Sectors In Dermatology
11.2.3.2 Personalised Dermatology: Technological Advances In Genomics
11.2.3.3 Advances In Topical Drug Delivery Methods Offers Product Differentiation
11.2.3.4 Consolidation Within Dermatology – Opportunity For Synergistic Growth?
11.2.4 Threats
11.2.4.1 Uncertain Surrounding Reimbursement And Payment Approvals
11.2.4.2 The Rising Cost Of Research And Development
11.2.4.3 Downward Pressures On Drug Prices
11.3 Porter’s Five Force Analysis Of The Global Dermatological Drugs Market, 2015-2025
11.3.1 Threat Of New Entrants
11.3.2 Threat Of Substitutes
11.3.3 Rivalry Among Competitors
11.3.4 Power Of Buyers
11.3.5 Power Of Suppliers

12. Expert Opinions from Our Primary Research
12.1 Interview With Kathleen Deardorff, Chief Operating Officer At Photocure ASA
12.1.1 Visonac As An Innovative First-In-Class Treatment
12.1.2 Photocure’s Development Plans For Visonac
12.1.3 Commercialisation Strategy For Visonac
12.1.4 On The Geographical Reach Of Acne Treatments
12.1.5 The Key Unmet Needs Within Patient Populations For Acne
12.1.6 The Key Forces Driving And Restraining The Development Of Acne Therapies
12.1.7 On The Current Development Pipeline For Acne Therapies
12.1.8 On Photocure’s Plans For Future Growth
12.1.9 Future Prospects For The Acne Treatments Market

13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
13.2 Leading Sectors In Dermatological Drugs In 2014
13.3 Leading Regions In The Dermatological Drugs Market In 2014
13.4 Future Outlook For The Various Sectors Within The Dermatological Drugs Market, 2015-2025
13.5 What Does The Future Hold For Dermatological Drugs?


【レポート販売概要】

■ タイトル:皮膚科用薬剤の世界市場:皮膚感染症薬、皮膚炎薬、にきび薬、乾癬薬
■ 英文:Dermatological Drugs Market Forecast 2015-2025 : Opportunities for Leading Companies
■ 発行日:2015年5月
■ 調査会社:visiongain
■ 商品コード:VGAIN5052605
■ 調査対象地域:グローバル
  • 高性能合金の世界市場:高融点金属合金、非鉄合金、超合金、白金族合金
    According to Stratistics MRC, the high performance alloys market is estimated at $7.51 billion in 2015 and is projected to reach $10.73 billion by 2022 growing at a CAGR of 5.22% from 2015 to 2022. Increasing demand from aerospace and automotive industry, rising demand for value-added products and rapid growth in emerging regions are some of the factors driving the market growth. Furthermore, tech …
  • 世界における小型自動車用OE(メーカー純正部品)基礎ブレーキ装置市場動向と予測(~2029)
    This latest just-auto report edition offers a global review of the OE foundation braking sector, its suppliers, top markets, technologies and market forecasts. This global market study offers: Automotive OE foundation braking market size estimates Latest technologies and trends Market share data tables Exclusive interviews with major companies Profiles of the major players including their strategi …
  • 非ホジキンリンパ腫(NHL)治療薬の世界市場:革新的なライセンシング機会
    Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma Summary Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means …
  • San Juan Basin Royalty Trust:石油・ガスの開発・生産動向及びコスト分析- 2012
    San Juan Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis - 2012 Summary San Juan Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essent …
  • アメリカの抗凝固剤市場2016-2020
    About the Anti-Coagulant Drugs Market Anticoagulants have been used for over 80 years to treat clotting disorders. It is used as a first line of defense for disorders such as deep vein thrombosis (DVT), pulmonary embolism, AF, and acute coronary syndrome. With the advent of time, traditional therapies are replaced by novel oral anticoagulants, which have better safety and efficacy profiles. The 19 …
  • 家電用耐擦傷性ガラス・コーティング剤の世界市場2019-2023
    About this market The increasing demand for innovative consumer electronics, especially smartphones and tablets, is leading to rapid changes in the market landscape. Smartphones and tablets have become inevitable, and their everyday use poses a risk of damage. Therefore, key manufacturers are focusing on developing multifunctional products. The multiple benefits of scratch-resistant glass and coat …
  • 世界の太陽光線制御被覆ガラス市場:用途別、地域別
    Global Coated Solar Control Glass Market: About this market Technavio’s coated solar control glass market analysis considers sales from commercial, residential, automotive, solar, and other applications. Our study also finds the sales of coated solar control glass in APAC, Europe, MEA, North America, and South America. In 2019, the commercial segment had a significant market share, and this trend …
  • 世界のケトン市場:用途別(サプリメント、食品&飲料、化粧品&パーソナルケア)、サプリメント種類別(ケトン塩、ケトンエステル、ケトンオイル、ラズベリーケトン)、フォーム別、地域別
    The ketone market is projected to grow at a CAGR of 6.3% from 2019 to 2025. The global ketone market is estimated to be valued at USD 443 million in 2019 and is projected to reach USD 640 million by 2025, recording a CAGR of 6.3%. The increase in the consumption of convenience food, rise in health consciousness among consumers, and multifunctionalities of ketones are some of the major factors that …
  • グリコヘモグロビン(HbA1c)検査の世界市場
    About Glycated Hemoglobin Testing Glycated hemoglobin helps measure the concentration of glucose in the blood of an individual. HbA1c, a specific chemical form of glycated hemoglobin, is used to determine a person's average blood glucose level over a period. It is a standardized test recommended by doctors for the diagnosis of type 2 diabetes or to test the control level of the blood glucose. The …
  • GeoMet, Inc.:石油・ガスの開発・生産動向及びコスト分析- Q3, 2013
    GeoMet, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary GeoMet, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key operation …
  • 2014年戦略提言:世界の潜血検査市場
    The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technolog …
  • Google Places vs. Facebook Places
    This report evaluates the two location-based services from Google and Facebook in terms of their use for marketing purposes by companies in B2C markets that have physical points of sale (referred in the report as “local businesses”). The report is written in a user-friendly (business/ marketing oriented) way and does not require technical knowledge.
  • モバイル端末向けアンチマルウェアソフトウェアの世界市場
    About Mobile Anti-Malware The internet has become significantly important in everyday life. Devices are at a greater risk of infection with different kinds of malware because of the increased use of the internet. Malware can come from different sources such as social media websites, e-mail spam, and websites that have unauthorized codes. Malware infections result in low performance and damage of t …
  • 屋内農業の世界市場展望2017-20276
    According to Stratistics MRC, the Global Indoor Farming market accounted for $106.6 billion in 2017 and is expected to reach $171.12 billion by 2026 growing at a CAGR of 5.4 % during the forecast period. Factors such as growing mechanisms in indoor farming and increasing focus on adopting innovative and efficient technologies are boosting the market growth. However, limitations on crop varieties a …
  • 質量分析法(MS)の世界市場予測(~2022年):種類、用途、地域別分析
    The global mass spectrometry market is expected to reach USD 5.27 Billion by 2022 from USD 3.68 Billion in 2017, at a CAGR of 7.4%. The growth of this market is majorly driven by technological advancements in mass spectrometry, government initiatives for pollution control and environmental testing, increasing spending on pharmaceutical R&D across the globe, government regulations on drug safety an …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。